FDA To Hold Public Meeting In February on Cosmetic Talc-Asbestos Test Methods
Recommendations from an FDA-led interagency work group regarding methods for detecting and measuring asbestos in talc and talc-containing cosmetics will be presented at the agency’s planned public meeting in Silver Spring, MD, on 4 February. The recommendations are summarized in the FDA's meeting notice, which follows contentious cosmetic product recalls based on asbestos findings.
You may also be interested in...
The FDA is focused on driving adoption of more sensitive, standardized testing methods for assessing cosmetic talc purity, which it believes would yield more consistent results across labs. This would help to inform research into the health implications of trace levels of asbestos and other elongate mineral particles in talc; in the interim it could to be damaging to companies that supply or use that talc.
The Personal Care Products Council says talc-testing methods in the cosmetics industry must distinguish between carcinogenic asbestos and harmless non-asbestiform minerals, recalling its position against the FDA’s stab at rulemaking in 1973. However, the FDA is now arguing that elongate mineral particles of respirable dimensions are inherently dangerous, regardless of other considerations.
J&J plans to cut 10% of its consumer health portfolio, with most divestitures in the baby and beauty care segments outside the US. It plans to focus on growing “stronghold” categories of skin health and self care, including Aveeno and Tylenol.